dockets: FDA-2026-P-10741

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

This data as json

id	agency_id	title	docket_type	last_modified	object_id	rin	dkabstract	category	subtype	keywords	program	short_title	effective_date	organization	attrs_raw	attr_source
FDA-2026-P-10741	FDA	Requests that the FDA require the sponsor of Trastuzumab to investigate whether the reported finding that approximately 68% of currently classified HER2-positive patients may not derive expected clinical benefit from trastuzumab is reproducible and to determine the extent and clinical significance of this finding.	Nonrulemaking	2026-09-15T12:53:18Z	0b000064b954fc97											list_pull

Links from other tables